Iron overload (IOL) due to transfusion-dependent anemia is a serious adverse effect in patients with myelofibrosis (MF). Recent studies have shown that the oral iron chelator deferasirox may prevent multiple organ damage due to IOL in MF. However, it is not clear whether deferasirox may contribute to revert transfusion-dependent anemia. Here, we present a patient with transfusion-dependent intermediate-2 MF according to the International Prognostic Scoring System treated with ruxolitinib in combination with deferasirox. In addition to a reduced serum ferritin level, the patient required less blood transfusions, ultimately resulting in long-lasting transfusion-free survival.

Keywords:
Myelofibrosis, Ruxolitinib, Deferasirox
1.
Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, Bauters F: Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013–1018.
2.
Tefferi A: Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management (review). Am J Hematol 2013; 88: 141–150; erratum 437–445.
3.
Leitch HA, Chase JM, Goodman TA, Ezzat H, Rollins MD, Wong DH, Badawi M, Leger CS, Ramadan KM, Barnett MJ, Foltz LM, Vickars LM: Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy. Hematol Oncol 2010; 28: 40–48.
4.
Kostos L, Chai KL, Tam CS, Bazargan A: The positive effect of deferasirox on erythropoiesis in a patient with a dual diagnosis of myelofibrosis and diffuse large B-cell lymphoma. Leuk Lymphoma 2017; 58: 2720–2723.
5.
Groepper S, Schlue J, Haferlach C, Giago-unidis A: Transfusion independency and histological remission in a patient with advanced primary myelofibrosis receiving iron-chelation therapy with deferasirox. Oncol Res Treat 2016; 39: 384–387.
6.
Kochhar H, Leger CS, Leitch HA: Durable red blood cell transfusion independence in a patient with an MDS/MPN overlap syndrome following discontinuation of iron chelation therapy. Case Rep Hematol 2015; 2015: 253294.
7.
Elli EM, Belotti A, Aroldi A, Parma M, Pioltelli P, Pogliani EM: Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis. Mediterr J Hematol Infect Dis 2014; 6:e2014042.
8.
Lisette del C, Enrico B, Eleonora A, Riccardo G, Manlio M, Omar R: Mayor erythropoietic response after deferasirox treatment in a transfusion-dependent anemic patient with primary myelofibrosis. Case Rep Hematol 2013; 2013: 520712.
9.
Tesch H, Ihling C: Loss of transfusion dependency following deferasirox treatment of iron overload in a woman with myelofibrosis and spherocytosis – a case report. Onkologie 2013; 36: 205–208.
10.
Matsuki E, Matsumoto K, Nakaya A, Yamane A, Kato J, Okamoto S: Marked improvement of anemia during treatment with deferasirox in patients with primary myelofibrosis and acute myeloid leukemia with myelodysplasia-related changes (in Japanese). Rinsho Ketsueki 2012; 53: 78–82.
11.
Capalbo S, Spinosa G, Franzese MG, Palumbo G: Early deferasirox treatment in a patient with myelodysplastic syndrome results in a long-term reduction in transfusion requirements. Acta Haematol 2009; 121: 19–20.
12.
Messa E, Cilloni D, Messa F, Arruga F, Roetto A, Saglio G: Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol 2008; 120: 70–74.
13.
Di Tucci AA, Murru R, Alberti D, Rabault B, Deplano S, Angelucci E: Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670). Eur J Haematol 2007; 78: 540–542.
14.
Latagliata R, Montagna C, Porrini R, Di Veroli A, Leonetti SC, Niscola P, Ciccone F, Spadea A, Breccia M, Maurillo L, Rago A, Spirito F, Cedrone M, De Muro M, Montana-ro M, Andriani A, Bagnato A, Montefusco E, Alimena G: Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase. Eur J Haematol 2016; 96: 643–649.
15.
Tataranni T, Agriesti F, Mazzoccoli C, Rug-gieri V, Scrima R, Laurenzana I, D’Auria F, Falzetti F, Di Ianni M, Musto P, Capitanio N, Piccoli C: The iron chelator deferasirox affects redox signalling in haematopoietic stem/progenitor cells. Br J Haematol 2015; 170: 236– 246.
16.
Massaro F, Molica M, Breccia M: How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes. Expert Rev Hematol 2017; 10: 155–159.
17.
Breccia M, Molica M, Colafigli G, Alimena G: Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug? Expert Rev Hematol 2015; 8: 387–389.
18.
Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, Finke C, Score J, Gangat N, Mannarelli C, Ketterling RP, Rotunno G, Knudson RA, Susini MC, Laborde RR, Spolverini A, Pancrazzi A, Pieri L, Manfredini R, Tagliafico E, Zini R, Jones A, Zoi K, Reiter A, Duncombe A, Pietra D, Rumi E, Cervantes F, Barosi G, Cazzola M, Cross NC, Tefferi A: Mutations and prognosis in primary myelofibrosis. Leukemia 2013; 27: 1861–1869.
19.
Musto P, Maurillo L, Simeon V, Poloni A, Finelli C, Balleari E, Ricco A, Rivellini F, Cortelezzi A, Tarantini G, Villani O, Mansueto G, Milella MR, Scapicchio D, Marziano G, Breccia M, Niscola P, Sanna A, Clissa C, Voso MT, Fenu S, Venditti A, Santini V, Angelucci E, Levis A: Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. Br J Haematol 2017; 177: 741–750.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.